The IMPARP trial investigates the combination of fluzoparib, camrelizumab and nanoparticle albumin-bound (nab) paclitaxel in HER2-negative HRD BC, with pCR as the measured endpoint [71]. This evidence concerns the gene ERBB2 and breast cancer.